| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant versus salvage radiotherapy: debates will be reignited
|
Spratt, D.E.
|
|
|
35 |
7 |
p. 585-587
|
artikel
|
| 2 |
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
|
Peters, S.
|
|
|
35 |
7 |
p. 607-629
|
artikel
|
| 3 |
Challenging immune exhaustion in early recurrent triple-negative breast cancer: pitfalls and hopes
|
Tarantino, P.
|
|
|
35 |
7 |
p. 579-581
|
artikel
|
| 4 |
Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality
|
Maddalena, G.
|
|
|
35 |
7 |
p. 678-680
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
35 |
7 |
p. iii
|
artikel
|
| 6 |
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
|
Ambrosini, M.
|
|
|
35 |
7 |
p. 643-655
|
artikel
|
| 7 |
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer
|
Dent, R.
|
|
|
35 |
7 |
p. 630-642
|
artikel
|
| 8 |
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
|
Pignata, S.
|
|
|
35 |
7 |
p. 667-676
|
artikel
|
| 9 |
Overcoming barriers in biomarker testing. Letter to the Editor regarding: ‘ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe’, by A. Bayle et al.
|
García-Foncillas, J.
|
|
|
35 |
7 |
p. 677-678
|
artikel
|
| 10 |
Proofreading the way: immune checkpoint inhibitors in polymerase ε/polymerase δ (POLE/POLD1)-altered colorectal cancer
|
Cecchini, M.
|
|
|
35 |
7 |
p. 582-584
|
artikel
|
| 11 |
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|
Mosele, M.F.
|
|
|
35 |
7 |
p. 588-606
|
artikel
|
| 12 |
Table of Contents
|
|
|
|
35 |
7 |
p. i-ii
|
artikel
|
| 13 |
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)
|
Parker, C.C.
|
|
|
35 |
7 |
p. 656-666
|
artikel
|
| 14 |
VP4-2024: First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
|
Bai, X.
|
|
|
35 |
7 |
p. 681-682
|
artikel
|
Tijdschrift beschrijving